MedTrace Logo

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-05-14

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).

Conditions

Interventions

DRUG

E2086

E2086 oral tablets.

DRUG

Placebo

E2086 matching placebo tablet.

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-26
Primary Completion
2027-02-14
Completion
2027-03-01
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • China
  • Germany
  • Italy
  • Japan
  • South Korea
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07493265 on ClinicalTrials.gov